» Articles » PMID: 21139040

The Bioflavonoid Kaempferol is an Abcg2 Substrate and Inhibits Abcg2-mediated Quercetin Efflux

Overview
Specialty Pharmacology
Date 2010 Dec 9
PMID 21139040
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

The flavonoids quercetin and kaempferol are major constituents of Ginkgo biloba extract. The ATP-binding cassette efflux transporter, breast cancer resistance protein (Bcrp, Abcg2), is involved in the transport of quercetin and represents a possible mechanism for the low bioavailability of quercetin. Our objective was to investigate whether kaempferol inhibits Bcrp-mediated quercetin efflux and determine whether it is a substrate for BCRP. The intracellular uptake of kaempferol, with and without specific inhibitors, was determined in Bcrp-expressing cells. The transport of quercetin or kaempferol (10 μM) across Madin-Darby canine kidney (MDCK) cell monolayers was investigated in both the apical (A)-to-basolateral (B) and B-to-A directions. Samples were analyzed using liquid chromatography-tandem mass spectrometry. Compared with the quercetin alone group, the transport ratio decreased 11.6-fold (from 97.5 to 8.37) in the presence of kaempferol in MDCK/Bcrp1 cells, indicating that kaempferol is a Bcrp inhibitor. The intracellular concentration of kaempferol was significantly increased in the presence of N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918), a potent Bcrp inhibitor, suggesting that kaempferol may also be a Bcrp substrate. Moreover, in MDCK/Bcrp1 cells, the P(app, B-A) of kaempferol was much higher (17.7 ± 3.8 × 10(-6) cm/s) than the P(app, A-B) (0.279 ± 0.037 × 10(-6) cm/s), with a transport ratio of 63.4. In contrast, the transport ratio of kaempferol was only 0.68 in Bcrp1-negative MDCK/Mock cells. We report for the first time that kaempferol is a Bcrp substrate, and our results indicate that kaempferol inhibits Bcrp-mediated quercetin efflux. Intestinal efflux by Bcrp may represent one possible mechanism for the low bioavailability of kaempferol. The use of flavonoids in combination may increase their bioavailability through transport interactions.

Citing Articles

Potential Nephroprotective Effect of Kaempferol: Biosynthesis, Mechanisms of Action, and Clinical Prospects.

Alkandahri M, Sadino A, Pamungkas B, Oktoba Z, Arfania M, Yuniarsih N Adv Pharmacol Pharm Sci. 2024; 2024:8907717.

PMID: 39377015 PMC: 11458287. DOI: 10.1155/2024/8907717.


Kaempferol ameliorates metabolic syndrome by inhibiting inflammation and oxidative stress in high-fat diet-induced obese mice.

Shin S, Kwon E Nutr Res Pract. 2024; 18(3):325-344.

PMID: 38854471 PMC: 11156765. DOI: 10.4162/nrp.2024.18.3.325.


Natural Products as a Tool to Modulate the Activity and Expression of Multidrug Resistance Proteins of Intestinal Barrier.

Martins-Gomes C, Silva A J Xenobiot. 2023; 13(2):172-192.

PMID: 37092502 PMC: 10123636. DOI: 10.3390/jox13020014.


Therapeutic Importance of Kaempferol in the Treatment of Cancer through the Modulation of Cell Signalling Pathways.

Qattan M, Khan M, Alharbi S, Verma A, Al-Saeed F, Abduallah A Molecules. 2022; 27(24).

PMID: 36557997 PMC: 9788613. DOI: 10.3390/molecules27248864.


Mechanisms of Kaempferol in the treatment of diabetes: A comprehensive and latest review.

Yang Y, Chen Z, Zhao X, Xie H, Du L, Gao H Front Endocrinol (Lausanne). 2022; 13:990299.

PMID: 36157449 PMC: 9490412. DOI: 10.3389/fendo.2022.990299.